News

BASF & CSM form joint venture
Enlarge image

BusinessGermanyNetherlands

BASF & CSM form joint venture

08.10.2012 - German chemicals giant and Dutch CSM daughter Purac have formed a
50/50 joint venture to produce and market biobased succinic acid.

The largest chemical firm of the world, BASF SE (Ludwigshafen, Gemany), and the leading producer of biobased lactic acid, Purac NV (Diemen, The Netherlands), a subsidiary of Dutch CSM, have formed a joint venture. After three years of testing of a novel fermentation process on pre-industrial scale at Purac’s production site in Montmélo near Barcelona, Succinity GmbH is going to start the production and sale of biobased succinic acid from 2013 . Succinity, which will be headquartered in Düsseldorf Germany, will be the third player in the market for biologically produced succinic acid, an important chemical building block for making 1,4-butanediol (1,4-BDO), tetrahydrofuran (THF) and gamma-butyrolactone (GBL). These bulk chemicals are needed for making polyesters, polyurethanes, spandex and biodegradable plastics with a global market value of more than $4bn.

BASF and CSM are currently expand Purac’s fermentation facility to deliver an annual capacity of 10,000 metric tons of succinic acid from late 2013. This is complemented by plans for a second large-scale facility with an annual capacity of 50,000 metric tons of succinic acid to enable the company to respond to the expected increase in demand. The final investment decision for this facility will be made following a successful market introduction, according to the companies.

Despite stiff competition from Reverdia, a joint-venture of Dutch DSM and French Roquette, and US-headquartered BioAmber Inc., BASF wants to take a leading position in the market. „The market is large enough for all players“, said BASF spokesman Holger Kapp to EuroBiotechNews. Earlier this year, Reverdia announced it will start biosuccinate production at the end of 2012. At the beginning of 2011, BioAmber had already started production of 2,000 metric tons of biosuccinate at its French production site in Pomacle and has since then expanded its production and its capacities to produce 1,4-BDO. However, BASF has brought in a unique production technology. Its proprietary microorganism Basfia succiniciproducens can make  biobased succinic acid either from plant-made sugars or by glycerol, a waste product form biodiesel production. This might give Succinity a competitive edge over the competitor’s technologies that can only convert crop- or plant-made sugars.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/basf-csm-form-joint-venture.html

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.

FinancingSwitzerlandEU

29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.

Industry reportGermany

27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).

Clinical ResearchFrancePortugal

21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.

Immuno-oncologyNetherlandsBelgium

21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.

RegulatorySwitzerlandEU

20.04.2016 The US government is forking out up to US$100m to get Basilea Pharmaceutica’s broad-spectrum antibiotic ceftobiprole on the US market. In the EU, ceftobiprole is already available.

Immuno-oncologyUK

19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.

FinancingSwitzerlandFranceEUGermanyDenmark

15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.

Event ReviewSwitzerlandBelgiumEU

13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

München

BioVaria 2016

Berlin (GER)

XIV. BIONNALE 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • KAROLINSKA (S)7.85 SEK9.03%

FLOP

  • PROTHENA PLC (IE)38.59 USD-7.15%
  • MEDIGENE (D)8.15 EUR-6.21%
  • ADOCIA (F)56.55 EUR-5.10%

TOP

  • SYNAIRGEN (UK)35.00 GBP45.8%
  • BIOFRONTERA (D)3.24 EUR38.5%
  • SWEDISH ORPHAN BIOVITRUM (S)15.24 USD27.5%

FLOP

  • EVOCUTIS (UK)0.05 GBP-28.6%
  • THERAMETRICS (CH)0.03 CHF-25.0%
  • SERODUS (N)1.50 NOK-23.9%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)28.40 SEK1793.3%
  • NICOX (F)8.27 EUR339.9%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)6.30 SEK-87.9%
  • BB BIOTECH (D)44.10 EUR-83.1%
  • CYTOS (CH)0.25 CHF-80.3%

No liability assumed, Date: 04.05.2016